The Akribion team is currently a dynamic mix of highly experienced scientists and executives with a passion for biotechnology and life sciences.
Our Technicians, Engineers and Project Leaders are the driving force behind everything we do and develop at Akribion Therapeutics.
When you enter our labs and offices, you sense a dynamic atmosphere.
We believe in our mission to develop groundbreaking therapeutic approaches for the treatment of complex and devastating diseases.
Lukas Linnig is the former CFO of BRAIN Biotech and former Executive Board Sponsor for Akribion. He embarked on the Akribion adventure because he firmly believes that Akribion´s technology can make a real difference in addressing major global challenges, such as the treatment of currently incurable diseases.
Lukas Linnig
Co-Founder & Co-CEO
Focus and Expertise With over 25 years in R&D of bioactive ingredients for food and cosmetic industries, Michael Krohn is a renowned figure in Industrial Biotechnology. His extensive peer-reviewed publications and numerous IP applications highlight his prowess in translational R&D.
Current Role and Responsibilities Michael is the Co-Founder and Co-CEO of Akribion Therapeutics. He also oversees national and international contract research, in-house R&D, B2B business development, and manages complex projects. He was part of the coordination team for the ‘NatLifE2020’ Innovation-Alliance, funded by the German Ministry for Education and Research, involving over 20 enterprises in a nearly decade-long collaboration.
Educational Background Michael holds a PhD in Molecular Biology from Heinrich-Heine University in Düsseldorf and has postdoctoral training from the Max-Planck Institute for Immunology in Freiburg.
“Leading the Frontier: Innovating Bioactive Solutions for a Healthier Future.”
Dr. Michael Krohn
Co-Founder & Co-CEO
Dr. Paul Scholz is the scientific leader of the gene editing program and the main inventor of the Gediting technology. He holds a PhD in biology and joined BRAIN Biotech AG in 2016 as head of the Applied Bioinformatics Platform. Paul enthusiastically combines metagenomics and bioinformatics to advance genome engineering.
Dr. Paul Scholz
Co-Founder & Head of R&D
Dr. Dirk Sombroek was head of the mammalian cell culture lab at BRAIN. He holds a PhD in Biology and joined BRAIN Biotech in 2010. Dirk is passionate about advancing Akribion’s technology. His priority is to establish partnerships that will accelerate this innovation towards clinical trials.
Dr. Dirk Sombroek
Head of Strategic Partnerships
Dr. Oliver Grünvogel is a former BCG strategy consultant and former Chief of Staff for a life science tech start-up. He holds a PhD in Biology and has been supporting the Akribion spinoff for several years. Oliver is excited about combining scientific curiosity and a strategic perspective to support the corporate development of Akribion.
Dr. Oliver Grünvogel
Head of Strategy & Operations
Adel Nada is the chair of Akribion board of directors. Adel is a seasoned biotech executive and serial entrepreneur. He is currently a venture partner with Volnay Therapeutics in Boston where he works on investing in and building new ventures around innovative technologies in cell and gene therapy. Adel is a multi-time cofounder, including GentiBio, Inc. a leading engineered regulatory T cells company, which he also led as CEO, through two rounds of VC financing and the first large pharma deal in the space with BMS. Previously, Adel served as senior executive in clinical development in multiple large and small companies, including Intellia Therapeutics, Baxter, and Abbott Labs. Adel started his career as an academic physician in Chicago where he practiced for 10 years before joining industry.
Adel Nada
Board Chair
Katharina works for the Life Sciences investment team of High-Tech Gründerfonds, one of the most active seed investors in Europe. She holds a PhD in medical biology and her passion to bring great science to life made her move to the venture capital world. Katharina typically invests in early-stage drug development companies that are rooted in exceptional science. She will offer her expertise as a board member of Akribion Therapeutics.
Dr. Katharina Severin
Board Member
Martin is a founder of CARMA FUND Management GmbH and initiated the fund in his role as managing director of the technology transfer firm Innovectis GmbH. Martin’s key role is covering investment decisions the investment team and the general management of the fund. Martin is a molecular biologist by training and holds a PhD from Max-Planck-Institute for medical research. Martin founded and held CEO positions in technology driven companies, served as ASTP president and had tenures as CEO technology transfer offices and as department head at BASF.
Dr. Martin Raditsch
Board Member
Alex holds a PhD degree in computational chemistry and MBA from Mannheim Business School. Alex brings more than 10 years of experience in the biotech space, being a co-founder of drug development startup himself and then moving to the VC side. He successfully invested in Biotech and Medtech startups from a VC fund RBV Capital and from CVC arm of tier 1 reinsurance company SCOR.
Dr. Alex Zeifman
Board Member
Feel free to reach out!